Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of 8.19 is 16% above its 5-year average of 7.06, near the high end of its 5-year range (2.77–8.94).
39.88% above its 12-month average of 5.85.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): 0.53.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 13 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-09-10T20:00:02.000Z. Historical observations retain their original dates. Historical series through 2026-09-09.
EARNINGS PER SHARE (EPS)
8.19
EARNINGS PER SHARE (EPS) AVG TTM
5.85
EARNINGS PER SHARE (EPS) AVG 3Y
6.82
EARNINGS PER SHARE (EPS) AVG 5Y
7.06
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+39.88%
CURRENT VS 3Y AVG
+20.04%
CURRENT VS 5Y AVG
+16.01%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Solventum Corporation
Market Cap
$15.18B
Earnings Per Share (EPS)
8.19
TTM Avg
5.85
3Y Avg
6.82
5Y Avg
7.06
Market Cap
$14.44B
Earnings Per Share (EPS)
3.19
TTM Avg
2.34
3Y Avg
1.78
5Y Avg
1.33
Market Cap
$16.28B
Earnings Per Share (EPS)
17.07
TTM Avg
14.35
3Y Avg
11.37
5Y Avg
9.10
Market Cap
$13.49B
Earnings Per Share (EPS)
2.10
TTM Avg
2.25
3Y Avg
2.01
5Y Avg
3.78
Market Cap
$13.15B
Earnings Per Share (EPS)
-4.85
TTM Avg
-1.35
3Y Avg
4.03
5Y Avg
5.21
Market Cap
$12.52B
Earnings Per Share (EPS)
4.07
TTM Avg
2.47
3Y Avg
1.81
5Y Avg
1.14
Market Cap
$12.50B
Earnings Per Share (EPS)
-2.04
TTM Avg
-1.51
3Y Avg
-0.65
5Y Avg
0.36
Market Cap
$17.88B
Earnings Per Share (EPS)
4.11
TTM Avg
4.00
3Y Avg
3.51
5Y Avg
2.55
Market Cap
$12.01B
Earnings Per Share (EPS)
6.14
TTM Avg
5.08
3Y Avg
4.10
5Y Avg
3.91
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Solventum Corporation (SOLV) | $15.18B | 8.19 | 5.85 | 6.82 | 7.06 |
| Exelixis, Inc. (EXEL)vs › | $14.44B | 3.19 | 2.34 | 1.78 | 1.33 |
| Medpace Holdings, Inc. (MEDP)vs › | $16.28B | 17.07 | 14.35 | 11.37 | 9.10 |
| Revvity, Inc. (RVTY)vs › | $13.49B | 2.10 | 2.25 | 2.01 | 3.78 |
| Charles River Laboratories International, Inc. (CRL)vs › | $13.15B | -4.85 | -1.35 | 4.03 | 5.21 |
| Penumbra, Inc. (PEN)vs › | $12.52B | 4.07 | 2.47 | 1.81 | 1.14 |
| Baxter International Inc. (BAX)vs › | $12.50B | -2.04 | -1.51 | -0.65 | 0.36 |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $17.88B | 4.11 | 4.00 | 3.51 | 2.55 |
| Encompass Health Corporation (EHC)vs › | $12.01B | 6.14 | 5.08 | 4.10 | 3.91 |
| DaVita Inc. (DVA)vs › | $11.64B | 11.38 | 10.37 | 8.56 | 8.35 |
Trailing EPS (TTM)
$8.19
Forward EPS (Est.)
$7.16
P/E Ratio
10.7
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | 8.94 |
| 2024-12-31 | 2.77 |
| 2023-12-31 | 7.79 |
| 2022-12-31 | 7.79 |
| 2021-12-31 | 8.47 |
| 2020-12-31 | 6.60 |
